Details for Patent: 7,875,630

« Back to Dashboard

Which drugs does patent 7,875,630 protect, and when does it expire?

Patent 7,875,630 protects ALTABAX and is included in one NDA.

This patent has thirteen patent family members in six countries.

Summary for Patent: 7,875,630

Title:	Process salts compositions and use
Abstract:	The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.
Inventor(s):	Gary Francis Breen, Michael Anthony Forth, Susan ShuMei Hu Kopelman, Francis Xavier Muller, Francis Dominic Sanderson
Assignee:	Almirall SA , Glaxo Group Ltd
Application Number:	US10/570,410
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 7,875,630

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Almirall	ALTABAX	retapamulin	OINTMENT;TOPICAL	022055-001	Apr 12, 2007		DISCN	Yes	No	7,875,630			Y

Foreign Priority and PCT Information for Patent: 7,875,630

PCT Information
PCT Filed	August 30, 2004	PCT Application Number:	PCT/US2004/028159
PCT Publication Date:	March 17, 2005	PCT Publication Number:	WO2005/023257

International Family Members for US Patent 7,875,630

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	450535
Germany	602004024417
European Patent Office	1663220
European Patent Office	2181995
Spain	2335284
Japan	2007504231